MED (Medifast) EBIT: $-16.2 Mil (TTM As of Mar. 2026)


MED Medifast Inc MED
69 GF Score
Price $10.36
GF Value $8.75
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medifast EBIT?

Medifast MED -2.45% 69 EBIT is $-16.2 Mil as of Mar. 2026. GuruFocus rates MED with a GF Score™ of 69/100 and a GF Value™ of $8.75 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Medifast's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medifast's annualized ROC % for the quarter that ended in Mar. 2026 was -25.20%. Medifast's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -32.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medifast's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 43.15%.


Medifast  (NYSE:MED) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medifast's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-13.18 * ( 1 - 0% )/( (51.277 + 53.336)/ 2 )
=-13.18/52.3065
=-25.20 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=247.973 - 37.975 - ( 167.273 - max(0, 42.962 - 201.683+167.273))
=51.277

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medifast's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.18/( ( (38.462 + max(-3.949, 0)) + (42.564 + max(-4.58, 0)) )/ 2 )
=-13.18/( ( 38.462 + 42.564 )/ 2 )
=-13.18/40.513
=-32.53 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 20.228 + 14.182) - (37.975 + 0.384 + 0)
=-3.949

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 21.403 + 12.281) - (38.264 + 0 + -7.105427357601E-15)
=-4.58

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medifast's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-16.245/-37.651
=43.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medifast EBIT Related Terms


Medifast EBIT Historical Data

* Premium members only.

The historical data trend for Medifast's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast EBIT Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.24 184.76 126.40 2.88 -14.21

Medifast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -1.07 -4.08 -7.80 -3.30

MED vs RGS, VGES, EVTK: EBIT Comparison

For the Personal Services subindustry, Medifast's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medifast EV-to-EBIT vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medifast's EV-to-EBIT falls into.


MED
69GF Score
Medifast Inc MED
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-16.2 Mil mean?
Medifast (MED) has a EBIT of $-16.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medifast.
Is Medifast's EBIT too high?
Medifast's current EBIT is $-16.2 Mil. Overall, Medifast has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's EBIT compare to RGS and VGES?
Medifast's EBIT of $-16.2 Mil can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Personal Services company?
A good EBIT depends on the Personal Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medifast. Medifast's current EBIT is $-16.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (MED) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.75, compared to a current price of $10.36 — trading 18.4% above its estimated fair value. The current EBIT is $-16.2 Mil. Medifast's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medifast (MED), the current EBIT is $-16.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medifast (MED) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of $10.36 is trading 18.4% above its estimated GF Value™ of $8.75. GuruFocus considers Medifast to be Modestly Overvalued.

Key valuation signals for MED:

  • EBIT: $-16.2 Mil
  • GF Value™: $8.75 vs. price of $10.36 (18.4% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medifast Business Description

Other Exchanges 0K05:UKMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
69GF Score

Get the complete analysis for MED

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.36
Price
$8.75
GF Value